Cargando…
Neutralizing antibody activity against 21 SARS-CoV-2 variants in older adults vaccinated with BNT162b2
SARS-CoV-2 variants may threaten the effectiveness of vaccines and antivirals to mitigate serious COVID-19 disease. This is of most concern in clinically vulnerable groups such as older adults. We analysed 72 sera samples from 37 individuals, aged 70–89 years, vaccinated with two doses of BNT162b2 (...
Autores principales: | Newman, Joseph, Thakur, Nazia, Peacock, Thomas P., Bialy, Dagmara, Elrefaey, Ahmed M. E., Bogaardt, Carlijn, Horton, Daniel L., Ho, Sammy, Kankeyan, Thivya, Carr, Christine, Hoschler, Katja, Barclay, Wendy S., Amirthalingam, Gayatri, Brown, Kevin E., Charleston, Bryan, Bailey, Dalan |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Nature Publishing Group UK
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9352594/ https://www.ncbi.nlm.nih.gov/pubmed/35836002 http://dx.doi.org/10.1038/s41564-022-01163-3 |
Ejemplares similares
-
Extended interval BNT162b2 vaccination enhances peak antibody generation
por: Parry, Helen, et al.
Publicado: (2022) -
Differential immunogenicity of BNT162b2 or ChAdOx1 vaccines after extended-interval homologous dual vaccination in older people
por: Parry, Helen, et al.
Publicado: (2021) -
Pseudotyped Bat Coronavirus RaTG13 is efficiently neutralised by convalescent sera from SARS-CoV-2 infected patients
por: Cantoni, Diego, et al.
Publicado: (2022) -
Influence of a Heterologous (ChAdOx1-nCoV-19/BNT162b2) or Homologous (BNT162b2/BNT162b2) Vaccination Regimen on the Antibody and T Cell Response to a Third Vaccination with BNT162b2
por: Reiter, Rieke, et al.
Publicado: (2022) -
Longitudinal Analysis of SARS-CoV-2-Specific Cellular and Humoral Immune Responses and Breakthrough Infection following BNT162b2/BNT162b2/BNT162b2 and ChAdOx1/ChAdOx1/BNT162b2 Vaccination: A Prospective Cohort in Naive Healthcare Workers
por: Ko, Geon Young, et al.
Publicado: (2023)